STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today
that it will host a conference call to discuss its fiscal 2023
fourth quarter and full year financial results at 9:00 a.m. ET on
May 11, 2023. The conference call can be heard live at
www.steris-ir.com or via phone by dialing 1-833-535-2199 in the
United States or 1-412-902-6776 internationally, then asking to
join the conference call for STERIS plc.
A press release detailing financial results will be issued after
the U.S. market closes on May 10, 2023.
For those unable to listen to the conference call live, a replay
will be available beginning at 12:00 p.m. ET on May 11, 2023,
either at www.steris-ir.com or via phone. To access the replay of
the call, please use the access code 1246295 and dial
1-877-344-7529 in the United States or 1-412-317-0088
internationally.
About STERIS
STERIS is a leading global provider of products and services
that support patient care with an emphasis on infection prevention.
WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by
providing innovative healthcare, life sciences and dental products
and services. For more information, visit
www.steris.com.
Company Contact:
Julie Winter, Vice President, Investor Relations and Corporate
Communications
Julie_Winter@steris.com
+1.440.392.7245
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING
INFORMATION
The release and the referenced conference call may contain
statements concerning certain trends, expectations, forecasts,
estimates, or other forward-looking information affecting or
relating to STERIS or its industry, products or activities that are
intended to qualify for the protections afforded “forward-looking
statements” under the Private Securities Litigation Reform Act of
1995 and other laws and regulations. Forward-looking statements
speak only as to the date the statement is made and may be
identified by the use of forward-looking terms such as “may,”
“will,” “expects,” “believes,” “anticipates,” “plans,” “estimates,”
“projects,” “targets,” “forecasts,” “outlook,” “impact,”
“potential,” “confidence,” “improve,” “optimistic,” “deliver,”
“orders,” “backlog,” “comfortable,” “trend”, and “seeks,” or the
negative of such terms or other variations on such terms or
comparable terminology. Many important factors could cause actual
results to differ materially from those in the forward-looking
statements including, without limitation, disruption of production
or supplies, changes in market conditions, political events,
pending or future claims or litigation, competitive factors,
technology advances, actions of regulatory agencies, and changes in
laws, government regulations, labeling or product approvals or the
application or interpretation thereof. Other risk factors are
described in STERIS’s other securities filings, including Item 1A
of our Annual Report on Form 10-K for the year ended March 31, 2022
and subsequently filed Quarterly Reports on Form 10-Q. Many of
these important factors are outside of STERIS’s control. No
assurances can be provided as to any result or the timing of any
outcome regarding matters described in STERIS’s securities filings
or otherwise with respect to any regulatory action, administrative
proceedings, government investigations, litigation, warning
letters, cost reductions, business strategies, earnings or revenue
trends or future financial results. References to products are
summaries only and should not be considered the specific terms of
the product clearance or literature. Unless legally required,
STERIS does not undertake to update or revise any forward-looking
statements even if events make clear that any projected results,
express or implied, will not be realized. Other potential risks and
uncertainties that could cause actual results to differ materially
from those in the forward-looking statements include, without
limitation, (a) the impact of the COVID-19 pandemic or similar
public health crises on STERIS’s operations, supply chain, material
and labor costs, performance, results, prospects, or value, (b)
STERIS's ability to achieve the expected benefits regarding the
accounting and tax treatments of the redomiciliation to Ireland
(“Redomiciliation”), (c) operating costs, Customer loss and
business disruption (including, without limitation, difficulties in
maintaining relationships with employees, Customers, clients or
suppliers) being greater than expected, (d) STERIS’s ability to
successfully integrate the businesses of Cantel Medical into our
existing businesses, including unknown or inestimable liabilities,
or increases in expected integration costs or difficulties in
connection with the integration of Cantel Medical, (e) STERIS’s
ability to meet expectations regarding the accounting and tax
treatment of the Tax Cuts and Jobs Act (“TCJA”) or the possibility
that anticipated benefits resulting from the TCJA will be less than
estimated, (f) changes in tax laws or interpretations that could
increase our consolidated tax liabilities, including changes in tax
laws that would result in STERIS being treated as a domestic
corporation for United States federal tax purposes, (g) the impact
of inflation and the potential for increased pressure on pricing or
costs that leads to erosion of profit margins, (h) the possibility
that market demand will not develop for new technologies, products
or applications or services, or business initiatives will take
longer, cost more or produce lower benefits than anticipated, (i)
the possibility that application of or compliance with laws, court
rulings, certifications, regulations, regulatory actions, including
without limitation any of the same relating to FDA, EPA or other
regulatory authorities, government investigations, the outcome of
any pending or threatened FDA, EPA or other regulatory warning
notices, actions, requests, inspections or submissions, or other
requirements or standards may delay, limit or prevent new product
or service introductions, affect the production, supply and/or
marketing of existing products or services or otherwise affect
STERIS’s performance, results, prospects or value, (j) the
potential of international unrest, including the Russia-Ukraine
military conflict, economic downturn or effects of currencies, tax
assessments, tariffs and/or other trade barriers, adjustments or
anticipated rates, raw material costs or availability, benefit or
retirement plan costs, or other regulatory compliance costs, (k)
the possibility of reduced demand, or reductions in the rate of
growth in demand, for STERIS’s products and services, (l) the
possibility of delays in receipt of orders, order cancellations, or
delays in the manufacture or shipment of ordered products, due to
supply chain issues or otherwise, or in the provision of services,
(m) the possibility that anticipated growth, cost savings, new
product acceptance, performance or approvals, or other results may
not be achieved, or that transition, labor, competition, timing,
execution, regulatory, governmental, or other issues or risks
associated with STERIS’s businesses, industry or initiatives
including, without limitation, those matters described in our
Annual Report on Form 10-K for the year ended March 31, 2022, and
other securities filings, may adversely impact STERIS’s
performance, results, prospects or value, (n) the impact on STERIS
and its operations, or tax liabilities, of Brexit or the exit of
other member countries from the EU, and the Company’s ability to
respond to such impacts, (o) the impact on STERIS and its
operations of any legislation, regulations or orders, including but
not limited to any new trade or tax legislation, regulations or
orders, that may be implemented by the U.S. administration or
Congress, or of any responses thereto, (p) the possibility that
anticipated financial results or benefits of recent acquisitions,
including the acquisition of Cantel Medical and Key Surgical, or of
STERIS’s restructuring efforts, or of recent divestitures,
including anticipated revenue, productivity improvement, cost
savings, growth synergies and other anticipated benefits, will not
be realized or will be other than anticipated, (q) the increased
level of STERIS’s indebtedness incurred in connection with the
acquisition of Cantel Medical limiting financial flexibility or
increasing future borrowing costs, (r) rating agency actions or
other occurrences that could affect STERIS’s existing debt or
future ability to borrow funds at rates favorable to STERIS or at
all, (s) the potential impact of the acquisition of Cantel Medical
on relationships, including with suppliers, Customers, employees
and regulators, and (t) the effects of contractions in credit
availability, as well as the ability of STERIS’s Customers and
suppliers to adequately access the credit markets when needed.
STERIS (NYSE:STE)
Historical Stock Chart
From Jun 2024 to Jul 2024
STERIS (NYSE:STE)
Historical Stock Chart
From Jul 2023 to Jul 2024